Palvella Therapeutics 10K 2022 Annual report | PVLA Filing

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: alleviate, Bank, bioprinting, blinded, Boehringer, broader, ciliated, circumvent, complementary, Connecticut, COPD, counterparty, CPI, CTSA, cystic, database, discretionary, elarekibep, FDIC, franchise, Franklin, gate, goblet, house, housed, hypersecretion, Ingelheim, IRA, language, lifetime, Mabcalin, metaplasia, microphysiological, middle, mucin, Notch, obstruction, obstructive, paragraph, pathogenic, PBM, plugging, Purple, readout, receivership, reforecast, reverted, secretory, Signature, silico, Silicon, Silvergate, slight, source, SVB, sweeping, titled, top, uninsured, Utah, Valley, volunteer

Removed: abandoned, activated, adenocarcinoma, agonism, announcement, APC, apolipoprotein, assumed, Attornment, attributed, avidin, bankruptcy, Berenberg, bifunctional, Biomedical, bipartisan, brand, bridged, capecitabine, Century, Chapter, chemotherapy, circle, cisplatin, CLP, cognate, comparative, compel, connected, constant, constitutionality, constitutively, constructed, construction, contractor, cornerstone, curve, deruxtecan, developer, devoid, differentially, differentiated, dish, displayed, disrupting, dotted, dual, electrochemoluminescence, elevate, emtansine, engrafted, enhancing, Enumeral, envisioned, exhaled, expensed, Experimental, explore, Fab, Fcg, filled, firstly, fitted, fractional, Freising, fulfilling, gastroesophageal, GEJ, grown, hampered, histocompatibility, hour, hypothesized, IFN, immunoassay, IMPD, incorporating, Incyte, INF, infiltration, Interestingly, interfere, invoking, isotype, kill, killer, lapse, linker, lymphocyte, MAHOGANY, manageable, margetuximab, MHC, microtiter, modernize, modifying, monomeric, mononuclear, move, nitric, NK, Notably, overnight, oxide, PBMC, pertuzumab, petition, piece, plastic, plate, precluded, precoated, preferentially, prerequisite, proinflammatory, prominent, proving, PRS, purified, reauthorization, reauthorized, Recombinant, refused, relief, repealing, Restoring, rituximab, room, sandwich, selectively, sigmoid, spared, spur, spurred, Subtenant, sue, supernatant, TCR, tethered, TGI, titrated, titration, trastuzumab, Trialtrove, Trump, twelve, unusually, upheld, variant, visualization, visualized, window


Entity		Jurisdiction of Organization
Pieris Pharmaceuticals GmbH		Germany
Pieris Australia Pty Limited		Australia
Pieris Pharmaceuticals Securities Corporation		Massachusetts

Palvella Therapeutics (PVLA) 10-K2022 FY Annual report

Content analysis